What's happened?
Optiscan Imaging Limited (ASX:OIL) has been awarded a grant of almost $1 million by the Australian Government, which will help fund a trial to improve screening, diagnosis and treatment of oral cancer.
What are the key highlights?
- The BioMedTech Horizons Program is an initiative of the Medical Research Future Fund, operated by MTPConnect.
- The Program’s latest round of funding, was open to medical device projects targeting innovative solutions to address unmet clinical needs in three key focus areas, including general medical devices in oncology.
- The $971,000 BioMedTech Horizons Program grant to OptiScan will enable the University of Melbourne’s Melbourne Dental School to undertake a trial with approximately 150 patients over a 12-month period.
For further information please refer to the announcement linked below.